Latest news and press releases about Nurix Therapeutics, Inc. (NRIX): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases.
Price
| Price | $24.83 |
| Market Cap | $2.6B |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 6.85 |
| EV / EBITDA | -8.13 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -76.09% |
| Return on Invested Capital | -77.32% |
| Return on Assets | -63.74% |
| Gross Margin | -165.51% |
| Operating Margin | -982.37% |
| Net Margin | -928.44% |
Related companies: BBOT · EYPT · FTRE · KOD · KURA · PHAT · SEPN
Explore sector: Healthcare · Biotechnology
More sections of NRIX: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks